Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukemias

Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis

Leukemia volume 20, pages 1009–1016 (2006)Cite this article

Abstract

All-trans retinoic acid (ATRA) induces differentiation of NB4 and HL-60 leukemia cells, but not R4 and HL-60/Res cells. Three agents used in cancer therapy, doxorubicin (Dox), arsenic trioxide (As2O3) and paclitaxel, induce apoptosis, but not differentiation, in all of these cell lines. The induction of apoptosis by these agents is decreased in ATRA-pretreated NB4 and HL-60 cells, but not in ATRA-pretreated R4 and HL-60/Res cells. The level of Bcl-2 protein is decreased by ATRA treatment in NB4, HL-60 and HL-60/Res cells. The level of Mcl-1 protein is increased by ATRA treatment in NB4 and R4 cells, but not in HL-60 and HL-60/Res cells. Bfl-1/A1 mRNA is not expressed in these cell lines, however, its expression is markedly induced by ATRA treatment in NB4 and HL-60 cells, but not in R4 or HL-60/Res cells, which correlates with inhibition of apoptosis. Inhibiting Bfl-1/A1 mRNA upregulation in ATRA-pretreated NB4 cells using small interfering RNA (siRNA) partly recovers cell sensitivity to Dox-induced apoptosis. These data demonstrate that ATRA induction of Bfl-1/A1 in differentiated NB4 and HL-60 cells contributes to a loss of sensitivity to chemotherapy-induced apoptosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572.

    CAS  PubMed  Google Scholar 

  2. Warrell Jr RP, Frankel SR, Miller Jr WH, Scheinberg DA, Itri LM, Hittelman WN et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385–1393.

    Article  PubMed  Google Scholar 

  3. Degos L, Dombret H, Chomienne C, Daniel MT, Miclea JM, Chastang C et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643–2653.

    CAS  PubMed  Google Scholar 

  4. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90: 1014–1021.

    CAS  PubMed  Google Scholar 

  5. Fenaux P, Chomienne C, Degos L . All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001; 38: 13–25.

    Article  CAS  PubMed  Google Scholar 

  6. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360.

    CAS  PubMed  Google Scholar 

  7. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–1348.

    Article  CAS  PubMed  Google Scholar 

  8. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324.

    CAS  PubMed  Google Scholar 

  9. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328–5335.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wang G, Li W, Cui J, Gao S, Yao C, Jiang Z et al. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol 2004; 22: 63–71.

    Article  PubMed  Google Scholar 

  11. Niitsu N, Ishii Y, Matsuda A, Honma Y . Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine. Cancer Res 2001; 61: 178–185.

    CAS  PubMed  Google Scholar 

  12. Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998; 91: 4300–4310.

    CAS  PubMed  Google Scholar 

  13. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124–133.

    Article  CAS  PubMed  Google Scholar 

  14. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97: 264–269.

    Article  CAS  PubMed  Google Scholar 

  15. Waxman S, Scher BM, Hellinger N, Scher W . Combination cytotoxic-differentiation therapy of mouse erythroleukemia cells with 5-fluorouracil and hexamethylene bisacetamide. Cancer Res 1990; 50: 3878–3887.

    CAS  PubMed  Google Scholar 

  16. Huang Y, Waxman S . Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate. Clin Cancer Res 1998; 4: 2503–2509.

    CAS  PubMed  Google Scholar 

  17. Miller Jr WH, Waxman S . Differentiation induction as a treatment for hematologic malignancies. Oncogene 2002; 21: 3496–3506.

    Article  CAS  PubMed  Google Scholar 

  18. Chen C, Lin H, Karanes C, Pettit GR, Chen BD . Human THP-1 monocytic leukemic cells induced to undergo monocytic differentiation by bryostatin 1 are refractory to proteasome inhibitor-induced apoptosis. Cancer Res 2000; 60: 4377–4385.

    CAS  PubMed  Google Scholar 

  19. Lombet A, Zujovic V, Kandouz M, Billardon C, Carvajal-Gonzalez S, Gompel A et al. Resistance to induced apoptosis in the human neuroblastoma cell line SK-N-SH in relation to neuronal differentiation. Role of Bcl-2 protein family. Eur J Biochem 2001; 268: 1352–1362.

    Article  CAS  PubMed  Google Scholar 

  20. McCarthy JV, Fernandes RS, Gotter TG . Increased resistance to apoptosis associated with HL-60 myeloid differentiation status. Anticancer Res 1994; 14: 2063–2072.

    CAS  PubMed  Google Scholar 

  21. Shore GC, Viallet J . Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology (Am Soc Hematol Educ Program) 2005, 226–230.

  22. Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D et al. The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 2002; 118: 521–534.

    Article  CAS  PubMed  Google Scholar 

  23. Monczak Y, Trudel M, Lamph WW, Miller Jr WH . Induction of apoptosis without differentiation by retinoic acid in PLB-985 cells requires the activation of both RAR and RXR. Blood 1997; 90: 3345–3355.

    CAS  PubMed  Google Scholar 

  24. Yin W, Raffelsberger W, Gronemeyer H . Retinoic acid determines life span of leukemic cells by inducing antagonistic apoptosis-regulatory programs. Int J Biochem Cell Biol 2005; 37: 1696–1708.

    Article  CAS  PubMed  Google Scholar 

  25. Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, Osorio LM . High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer 2005; 113: 730–737.

    Article  CAS  PubMed  Google Scholar 

  26. Kim H, Kim YN, Kim CW . Oxidative stress attenuates Fas-mediated apoptosis in Jurkat T cell line through Bfl-1 induction. Oncogene 2005; 24: 1252–1261.

    Article  CAS  PubMed  Google Scholar 

  27. Tarte K, Jourdan M, Veyrune JL, Berberich I, Fiol G, Redal N et al. The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. Br J Haematol 2004; 125: 373–382.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R . NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080–1086.

    CAS  PubMed  Google Scholar 

  29. Rosenauer A, Raelson JV, Nervi C, Eydoux P, DeBlasio A, Miller Jr WH . Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood 1996; 88: 2671–2682.

    CAS  PubMed  Google Scholar 

  30. Li YP, Said F, Gallagher RE . Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-alpha. Blood 1994; 83: 3298–3302.

    CAS  PubMed  Google Scholar 

  31. Dai J, Weinberg RS, Waxman S, Jing Y . Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268–277.

    CAS  PubMed  Google Scholar 

  32. Zhou L, Jing Y, Styblo M, Chen Z, Waxman S . Glutathione-S-transferase pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. Blood 2005; 105: 1198–1203.

    Article  CAS  PubMed  Google Scholar 

  33. Jing Y, Ohizumi H, Kawazoe N, Hashimoto S, Masuda Y, Nakajo S et al. Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells. Jpn J Cancer Res 1994; 85: 645–651.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Lin EY, Orlofsky A, Berger MS, Prystowsky MB . Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol 1993; 151: 1979–1988.

    CAS  PubMed  Google Scholar 

  35. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H . Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7: 680–686.

    Article  CAS  PubMed  Google Scholar 

  36. Tallman MS, Nabhan C, Feusner JH, Rowe JM . Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759–767.

    Article  CAS  PubMed  Google Scholar 

  37. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192–1200.

    CAS  PubMed  Google Scholar 

  38. Dombret H, Fenaux P, Soignet SL, Tallman MS . Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin Hematol 2002; 39: 8–13.

    Article  CAS  PubMed  Google Scholar 

  39. Laurent G, Jaffrezou JP . Signaling pathways activated by daunorubicin. Blood 2001; 98: 913–924.

    Article  CAS  PubMed  Google Scholar 

  40. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345–3353.

    CAS  PubMed  Google Scholar 

  41. Woo MH, Relling MV, Sonnichsen DS, Rivera GK, Pratt CB, Pui CH et al. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 1999; 5: 543–549.

    CAS  PubMed  Google Scholar 

  42. Hafid-Medheb K, Poindessous-Jazat V, Augery-Bourget Y, Hanania N, Robert-Lezenes J . Bcl-XL induction during terminal differentiation of friend erythroleukaemia cells correlates with delay of apoptosis and loss of proliferative capacity but not with haemoglobinization. Cell Death Differ 1999; 6: 166–174.

    Article  CAS  PubMed  Google Scholar 

  43. Chatterjee D, Han ZG, Mendoza J, Goodglick L, Hendrickson EA, Pantazis P et al. Monocytic differentiation of HL-60 promyelocytic leukemia cells correlates with the induction of Bc-xL. Cell Growth Differ 1997; 6: 166–174.

    Google Scholar 

  44. Benito A, Silva M, Grillot D, Nunez G, Fernandez-Luna JL . Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL . Blood 1996; 87: 3837–3843.

    CAS  PubMed  Google Scholar 

  45. Liu TX, Zhang JW, Tao J, Zhang RB, Zhang QH, Zhao CJ et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 2000; 96: 1496–1504.

    CAS  PubMed  Google Scholar 

  46. Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 1999; 96: 2907–2912.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Henson ES, Gibson EM, Villanueva J, Bristow NA, Haney N, Gibson SB . Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway. J Cell Biochem 2003; 89: 1177–1192.

    Article  CAS  PubMed  Google Scholar 

  48. Chao JR, Wang JM, Lee SF, Peng HW, Lin YH, Chou CH et al. mcl-1 is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol Cell Biol 1998; 18: 4883–4898.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C . The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13: 382–387.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. D'Sa-Eipper C, Subramanian T, Chinnadurai G . bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity. Cancer Res 1996; 56: 3879–3882.

    CAS  PubMed  Google Scholar 

  51. Carrio R, Lopez-Hoyos M, Jimeno J, Benedict MA, Merino R, Benito A et al. A1 demonstrates restricted tissue distribution during embryonic development and functions to protect against cell death. Am J Pathol 1996; 149: 2133–2142.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Shim YH, Byun EK, Lee MJ, Huh J, Kim CW . Anti-apoptotic role of Bfl-1 in staurosporine-treated B-lymphoblastic cells. Int J Hematol 2000; 72: 484–490.

    CAS  PubMed  Google Scholar 

  53. Cheng Q, Lee HH, Li Y, Parks TP, Cheng G . Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene 2000; 19: 4936–4940.

    Article  CAS  PubMed  Google Scholar 

  54. Tabe Y, Konopleva M, Contractor R, Igari J, Andreeff M . Upregulation of MDR1 and induction of doxorubicin resistance by synergistic use of histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 2003; 102: 3200 Part 3201.

    Google Scholar 

  55. Fenaux P, Chomienne C, Degos L . Treatment of acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2001; 14: 153–174.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was partly supported by NIH CA93533 and Samuel Waxman Cancer Research Foundation.

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA

    L Xia, E Wurmbach, S Waxman & Y Jing

Authors
  1. L Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Wurmbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Waxman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Jing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Jing.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xia, L., Wurmbach, E., Waxman, S. et al. Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis. Leukemia 20, 1009–1016 (2006). https://doi.org/10.1038/sj.leu.2404198

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404198

Keywords

This article is cited by

Search

Advanced search

Quick links